Eli Lilly’s decision to give two distinctive brand names to tirzepatide, which is approved for type 2 diabetes and now chronic weight management, indicates just how differently the company plans to market both indications.
Last week it announced that its weight management version of the drug is called Zepbound, while the same drug is branded as Mounjaro for type 2 diabetes.
“Patients living with diabetes and patients with obesity have different needs,” a Lilly spokesperson said in an email. “The different brands allow Lilly to educate and provide resources and tools in order for healthcare professionals and patients to start successfully on Zepbound.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
